Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
- PMID: 17637682
- PMCID: PMC2360336
- DOI: 10.1038/sj.bjc.6603889
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
Abstract
This phase II trial was performed to evaluate the efficacy and tolerability of oral tegafur-uracil (UFT) with leucovorin (LV) combined with intravenous (i.v.) irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC). Patients received oral UFT 250 mg m(-2) day(-1) and LV 90 mg day(-1) in three divided daily doses for 14 days followed by a 1-week rest and i.v. irinotecan 250 mg m(-2) as a 90-min infusion every 3 weeks. Tumour responses, assessed every two cycles using RECIST criteria, were reviewed by an independent review committee. In 52 evaluable patients, the best overall response rate was 33% (95% confidence intervals (CI) 20-47%; 1 complete and 16 partial responses). The median time to progression was 5.4 months (95% CI 3.02-7.52 months) and median overall survival was 14.9 months (11.73-17.97 months). A total of 307 cycles were administered, with a median number of five cycles per patient (range: 1-10). The most common grade 3/4 toxicities were neutropenia (25% of patients), diarrhoea (22%), vomiting (11%) and anaemia (11%). The TEGAFIRI regimen is a feasible, well-tolerated and convenient treatment option for patients with non-resectable mCRC.
Figures
Similar articles
-
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.Br J Cancer. 2007 Feb 12;96(3):439-44. doi: 10.1038/sj.bjc.6603493. Epub 2007 Jan 23. Br J Cancer. 2007. PMID: 17245343 Free PMC article. Clinical Trial.
-
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.Int J Cancer. 2016 Aug 15;139(4):946-54. doi: 10.1002/ijc.30127. Epub 2016 Apr 23. Int J Cancer. 2016. PMID: 27061810 Clinical Trial.
-
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.Ann Oncol. 2003 Aug;14(8):1264-9. doi: 10.1093/annonc/mdg340. Ann Oncol. 2003. PMID: 12881390 Clinical Trial.
-
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.Eur J Cancer. 2004 Mar;40(4):508-14. doi: 10.1016/j.ejca.2003.10.022. Eur J Cancer. 2004. PMID: 14962716 Clinical Trial.
-
The role of UFT in metastatic colorectal cancer.Oncology. 2009;76(5):301-10. doi: 10.1159/000209334. Epub 2009 Mar 20. Oncology. 2009. PMID: 19299903 Review.
Cited by
-
TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer.Oncol Lett. 2015 Mar;9(3):1059-1064. doi: 10.3892/ol.2015.2855. Epub 2015 Jan 7. Oncol Lett. 2015. PMID: 25663857 Free PMC article.
-
Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.Int J Med Sci. 2011;8(5):406-12. doi: 10.7150/ijms.8.406. Epub 2011 Jul 1. Int J Med Sci. 2011. PMID: 21750645 Free PMC article.
-
Response to Modified TEGAFIRI in a Patient with Synchronous Multiple Liver Metastases of Colon Cancer.Case Rep Gastroenterol. 2011 Jan;5(1):95-9. doi: 10.1159/000324399. Epub 2011 Feb 5. Case Rep Gastroenterol. 2011. PMID: 23136565 Free PMC article.
-
A phase I study of oral UFT/leucovorin and irinotecan, plus radiation for locally recurrent rectal cancer.J Anus Rectum Colon. 2018 May 25;1(2):50-55. doi: 10.23922/jarc.2016-009. eCollection 2017. J Anus Rectum Colon. 2018. PMID: 31583301 Free PMC article.
-
Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.Br J Cancer. 2008 Aug 19;99(4):577-83. doi: 10.1038/sj.bjc.6604499. Br J Cancer. 2008. PMID: 18682717 Free PMC article. Clinical Trial.
References
-
- Bennouna J, Perrier H, Paillot B, Priou F, Jacob JH, Hebbar H, Bordenave S, Seitz JF, Cvitkovic F, Dorval E, Malek K, Tonelli D, Douillard JY (2006) A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer 4: 69–73 - PMC - PubMed
-
- Bobbio-Pallavicini E, Porta C, Moroni M, Spaghi A, Casagranda I, Nastasi G (1993) Folinic acid does improve 5-fluorouracil activity in vivo: results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 5: 52–55 - PubMed
-
- Borner MM, Castiglione M, Bacchi M, Weber W, Herrmann R, Fey MF, Pagani O, Leyvraz S, Morant R, Pestalozzi B, Hanselmann S, Goldhirsch A (1998) The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of phase III trial. Ann Oncol 9: 535–541 - PubMed
-
- Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 348–358 - PubMed
-
- Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617–3627 - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical